CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases

Tempfer, Clemens; Hefler, Lukas; Heinzl, Harald; Loesch, Alexander; Gitsch, G.; Rumpold, Helmut; Kainz, Christian

doi:10.1038/bjc.1998.636

Cited by 17 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our experience preoperative serum CYFRA 21-1 assay, that detects fragments of cytokeratin 19, appeared to be predictive of response to chemotherapy but not prognostic of survival in patients with this malignancy [36]. Conversely, in the series of Tempfer et al [35] elevated pre-treatment CYFRA 21-1 levels were significantly related to poor disease-free survival and poor overall survival.…”

Section: Soluble Cytokeratin Fragmentsmentioning

confidence: 59%

“…Soluble forms of fragments of cytokeratins, which represent important structural elements of the cell cytoskeleton, have been identified in sera from patients with different malignancies, including EOC [35,36]. In our experience preoperative serum CYFRA 21-1 assay, that detects fragments of cytokeratin 19, appeared to be predictive of response to chemotherapy but not prognostic of survival in patients with this malignancy [36].…”

Section: Soluble Cytokeratin Fragmentsmentioning

confidence: 74%

See 1 more Smart Citation

Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer

Gadducci

Cosio

Tana

et al. 2009

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Soluble Cytokeratin Fragmentsmentioning

confidence: 59%

Section: Soluble Cytokeratin Fragmentsmentioning

confidence: 74%

Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer

Gadducci

Cosio

Tana

et al. 2009

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Mobus et al (27) found that ovarian cancer cell lines express large amounts of cytokeratin 19, suggesting that overexpression of cytokeratin 19 paralleled ovarian carcinogenesis. Few data are currently available in the literature about the clinical relevance of serum CYFRA 21-1 assay in the management of patients with ovarian cancer (12,13,22) . By assessing pretreatment serum tumor marker levels in 235 women with different gynecologic diseases, Inaba et al (13) observed that positivity rates for CYFRA 21-1 (cut-off = 1.9 ng/ml) were 64.0% in ovarian malignancy compared with 4.2% in benign ovarian masses.…”

Section: Serum Cyfra 21-1 In Ovarian Cancer Patients 279mentioning

confidence: 99%

“…Cytokeratin fragments exist also in soluble form and can be detected in the serum with the aid of monoclonal antibodies (5) . Soluble cytokeratin fragments have been investigated as tumor markers in several malignancies, including gynecologic cancer (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) . The biochemical pathway by which these fragments are formed in malignant tissues and released into the bloodstream is still uncertain (20) .…”

mentioning

confidence: 99%

See 1 more Smart Citation

The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer

Gadducci¹,

Ferdeghini²,

Cosio³

et al. 2001

Int J Gynecol Cancer

View full text Add to dashboard Cite

Abstract.Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer.CYFRA 21-1 assay, which detects serum fragments of cytokeratin 19, has been widely assessed as a serum marker of several malignancies. Preoperative serum CYFRA 21-1 levels were retrospectively measured in 60 patients with ovarian cancer and in 59 control patients with benign ovarian disease. CYFRA 21-1 levels were also serially measured in 90 serum samples drawn from patients with advanced (FIGO stage III-IV) ovarian cancer followed after surgery and chemotherapy. Preoperative serum CYFRA 21-1 levels were higher in patients with ovarian cancer compared with controls (median, range = 2.6, 0.1–51.4 ng/ml versus 0.4, 0.0–3.6 ng/ml, P < 0.0001), and among the former, antigen values were higher in the 39 patients with advanced-stage than in the 21 patients with early (FIGO stage I-II) disease (P < 0.0001). In advanced ovarian cancer patients, the 25%, 50%, and 75% quantiles of preoperative CYFRA 21-1 levels were 1.9, 4.8 and 14.4 ng/ml, respectively. Preoperative CYFRA 21-1 levels were lower in the 11 patients who achieved a pathologic complete response at second-look compared with those who had clinically or surgically detectable persistent disease after first-line chemotherapy (median, range 1.9, 0.6–9.2 ng/ml versus 10.2, 0.1–51.4 ng/ml, P = 0.007). The pathologic complete response rate was significantly greater in patients with low preoperative CYFRA 21-1 levels compared with those with elevated CYFRA 21-1 levels at any cut-off limit for the antigen (1.9, 4.8 and 14.4 ng/ml). However, Cox regression analysis failed to detect a significant association between preoperative CYFRA 21-1 assay and survival. As for the follow-up of advanced ovarian cancer patients, CYFRA 21-1 levels were higher in the 42 samples drawn from patients with clinically detectable disease compared with the 48 specimens collected from patients with no clinical evidence of disease (median, range = 1.15, 0.3–40.7 ng/ml versus 0.4, 0.1–9.1 ng/ml, P < 0.0001). In conclusion, preoperative serum CYFRA 21-1 assay appears to be predictive of response to chemotherapy, but not prognostic of survival, for patients with advanced ovarian cancer. Moreover, the serial measurement of CYFRA 21-1 levels might have a potential clinical relevance for the assessment of disease status in patients followed after surgery and chemotherapy.

show abstract